RT Journal Article
T1 Ruxolitinib in refractory acute and chronic graft-versus-host disease: a multicenter survey study.
A1 Escamilla Gómez, Virginia
A1 García-Gutiérrez, Valentín
A1 López Corral, Lucía
A1 García Cadenas, Irene
A1 Pérez Martínez, Ariadna
A1 Márquez Malaver, Francisco J
A1 Caballero-Velázquez, Teresa
A1 González Sierra, Pedro A
A1 Viguria Alegría, María C
A1 Parra Salinas, Ingrid M
A1 Calderón Cabrera, Cristina
A1 González Vicent, Marta
A1 Rodríguez Torres, Nancy
A1 Parody Porras, Rocío
A1 Ferra Coll, Christelle
A1 Orti, Guillermo
A1 Valcárcel Ferreiras, David
A1 De la Cámara LLanzá, Rafael
A1 Molés, Paula
A1 Velázquez-Kennedy, Kyra
A1 João Mende, María
A1 Caballero Barrigón, Dolores
A1 Pérez, Estefanía
A1 Martino Bofarull, Rodrigo
A1 Saavedra Gerosa, Silvanna
A1 Sierra, Jorge
A1 Poch, Marc
A1 Zudaire Ripa, María T
A1 Díaz Pérez, Miguel A
A1 Molina Angulo, Blanca
A1 Sánchez Ortega, Isabel
A1 Sanz Caballer, Jaime
A1 Montoro Gómez, Juan
A1 Espigado Tocino, Ildefonso
A1 Pérez-Simón, José A
A1 Grupo Español de Trasplante Hematopoyético (GETH), 
AB Graft-versus-host disease is the main cause of morbidity and mortality after allogeneic hematopoietic stem cell transplantation. First-line treatment is based on the use of high doses of corticosteroids. Unfortunately, second-line treatment for both acute and chronic graft-versus-host disease, remains a challenge. Ruxolitinib has been shown as an effective and safe treatment option for these patients. Seventy-nine patients received ruxolitinib and were evaluated in this retrospective and multicenter study. Twenty-three patients received ruxolitinib for refractory acute graft-versus-host disease after a median of 3 (range 1-5) previous lines of therapy. Overall response rate was 69.5% (16/23) which was obtained after a median of 2 weeks of treatment, and 21.7% (5/23) reached complete remission. Fifty-six patients were evaluated for refractory chronic graft-versus-host disease. The median number of previous lines of therapy was 3 (range 1-10). Overall response rate was 57.1% (32/56) with 3.5% (2/56) obtaining complete remission after a median of 4 weeks. Tapering of corticosteroids was possible in both acute (17/23, 73%) and chronic graft-versus-host disease (32/56, 57.1%) groups. Overall survival was 47% (CI: 23-67%) at 6 months for patients with aGVHD (62 vs 28% in responders vs non-responders) and 81% (CI: 63-89%) at 1 year for patients with cGVHD (83 vs 76% in responders vs non-responders). Ruxolitinib in the real life setting is an effective and safe treatment option for GVHD, with an ORR of 69.5% and 57.1% for refractory acute and chronic graft-versus-host disease, respectively, in heavily pretreated patients.
YR 2019
FD 2019-11-07
LK http://hdl.handle.net/10668/14653
UL http://hdl.handle.net/10668/14653
LA en
DS RISalud
RD Apr 10, 2025